ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INNT Innovate Biopharmaceuticals Inc

0.56
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Innovate Biopharmaceuticals Inc NASDAQ:INNT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.56 0.56 0.57 0 01:00:00

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

16/05/2017 11:05am

Edgar (US Regulatory)


U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

 

SEC File Number   001-37797

 

(Check One) :  Form 10-K  Form 20-F    Form 11-K    Form 10-Q    Form N-SAR    Form N-CSR  

 

For Period Ended:  March 31, 2017

 

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

 

For the Transition Period Ended:  _________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

Part I - Registrant Information

 

MONSTER DIGITAL, INC.

Full Name of Registrant

N/A

Former Name if Applicable

 

2655 First Street, Suite 250

Address of Principal Executive Office ( Street and Number)

 

Simi Valley, CA  93065

City, State and Zip

 

Part II - Rules 12b-25(b) and (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

 

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date: and
   
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable

 

 

 

Part III - Narrative

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.  (Attach Extra Sheets if Needed)

 

The registrant is unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2017 within the prescribed time period due to its difficulty in completing and obtaining required financial and other information without unreasonable effort and expense.  The registrant expects to file the Form 10-Q within the time period permitted by this extension.

 

Part IV - Other Information

 

(1)  Name and telephone number of person to contact in regard to this notification

 

     
David Olert 805 381-5469
(Name) (Area Code) (Telephone Number)

 

(2)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s).

 

Yes     No 

 

(3)  Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

Yes     No 

 

 

Monster Digital, Inc.

(Name of Registrant as Specified in Charter)

 

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:  May 16, 2017 By:  /s/ David Olert
  David Olert
  Chief Financial Officer

 

 

 

1 Year Innovate Biopharmaceutic... Chart

1 Year Innovate Biopharmaceutic... Chart

1 Month Innovate Biopharmaceutic... Chart

1 Month Innovate Biopharmaceutic... Chart

Your Recent History

Delayed Upgrade Clock